B7-33 (6mg) Peptide – Receptor-Grade Research Compound

B7-33 (6mg) is a synthetic peptide analog derived from the naturally occurring hormone relaxin-2, designed specifically for advanced cell signaling, inflammation, and fibrosis research. Developed to selectively activate the RXFP1 receptor, B7-33 has emerged as a valuable research compound due to its targeted receptor activity and reduced off-target effects when compared to full-length relaxin peptides.

At Core Peptide, our receptor-grade B7-33 (6mg) is manufactured to strict purity standards and supplied exclusively for laboratory and research use within the United States.

Background and Discovery of B7-33

Relaxin-2 is a naturally produced peptide hormone historically associated with reproductive biology, cardiovascular function, and connective tissue remodeling. Early research demonstrated that relaxin-2 could activate the relaxin family peptide receptor 1 (RXFP1), triggering intracellular signaling pathways involved in anti-fibrotic and anti-inflammatory responses.

However, the full relaxin-2 peptide also activates multiple downstream pathways, making it difficult for researchers to isolate specific signaling effects. To address this, researchers engineered B7-33, a truncated relaxin-2 analog designed to selectively stimulate RXFP1-mediated signaling while limiting activation of other pathways.

This targeted receptor activity has made B7-33 (6mg) an increasingly important peptide in mechanistic and translational research settings.

Mechanism of Action

B7-33 primarily exerts its research value through selective RXFP1 receptor activation. Upon receptor binding, researchers suggest B7-33 may initiate intracellular cascades involving:

• cAMP signaling pathways

• Nitric oxide (NO) modulation

• Reduced pro-fibrotic gene expression

Unlike full-length relaxin-2, B7-33 appears to bias receptor signaling toward pathways associated with tissue protection and remodeling, making it especially useful in fibrosis and inflammation studies.

Research Applications of B7-33 (6mg)

B7-33 and Fibrosis Research

Fibrosis is characterized by excessive extracellular matrix deposition and tissue stiffening. Multiple preclinical investigations suggest that RXFP1 activation may downregulate fibrotic signaling pathways such as TGF-β.

Researchers studying cardiac, renal, pulmonary, and hepatic fibrosis have explored B7-33 peptide as a tool to better understand how selective relaxin receptor activation influences collagen turnover and tissue elasticity.

B7-33 and Inflammatory Signaling

Inflammation is closely linked to chronic tissue damage and disease progression. B7-33 has been investigated in research models for its potential ability to modulate inflammatory cytokine expression without triggering broad systemic hormonal responses.

This selective activity makes B7-33 (6mg) especially valuable in controlled laboratory experiments where signaling specificity is critical.

Cardiovascular and Vascular Research

RXFP1 receptors are expressed in vascular tissue. Studies suggest that relaxin-based signaling may influence vascular tone, endothelial function, and nitric oxide production.

B7-33’s receptor-biased activity allows researchers to examine these mechanisms with reduced interference from secondary hormonal effects, supporting its use in cardiovascular research models.

Chemical Characteristics

• Product Name: B7-33

• Amount: 6mg

• Peptide Class: Relaxin-2 analog

• Purity: Receptor Grade

• Form: Lyophilized powder

Each vial of B7-33 (6mg) from Core Peptide is produced under controlled laboratory standards to ensure consistency, stability, and reproducibility in research environments.

Receptor Grade Quality at Core Peptide

The receptor-grade designation indicates a higher level of purity compared to general laboratory or media-grade peptides. This is essential for receptor-binding and cell signaling studies, where impurities may interfere with experimental outcomes.

Learn more about our quality standards on the
Core Peptide Research Peptides Collection

Comparison to Full-Length Relaxin-2

While full-length relaxin-2 peptides activate RXFP1, they may also trigger additional signaling cascades. B7-33 (6mg) was engineered to reduce this complexity, allowing researchers to:

• Study receptor-biased signaling

• Improve experimental specificity

• Reduce variability in signaling outcomes

This makes B7-33 particularly useful in mechanistic research rather than systemic hormone modeling.

Storage and Handling (Research Use)

For optimal stability in laboratory settings:

• Store lyophilized B7-33 at -20°C

• Reconstitute using sterile laboratory-grade solvents

• Avoid repeated freeze-thaw cycles

Always follow institutional handling protocols when working with research peptides.

Compliance and Research Use Disclaimer

B7-33 (6mg) sold by Core Peptide is intended for research and laboratory use only.
It is not approved for human or veterinary use.

Please review our
Terms and Conditions
before purchasing.

External Research References

• Teerlink JR et al., Relaxin and RXFP1 signaling in cardiovascular biology, Journal of Molecular and Cellular Cardiology

• Samuel CS et al., Relaxin peptides and anti-fibrotic signaling mechanisms, Endocrine Reviews

Why Choose Core Peptide for B7-33 (6mg)?

 USA-focused distribution
 Receptor-grade purity
Research-only compliance

Explore B7-33 (6mg) and other advanced research peptides today at
https://corepeptide.us